Does Cramer recommend buying JNJ stock?

Cramer expressed bullishness but did not give an explicit buy or sell recommendation.

What AI opportunities did Cramer mention?

Cramer mentioned AI opportunities in neoclouds as a potential tailwind for the healthcare sector.

Jim Cramer Expects Positive News for Johnson & Johnson Blockbuster Drugs

Jim Cramer highlighted Johnson & Johnson (JNJ) on Mad Money, expecting good news about its blockbuster drugs. He also noted AI opportunities in neoclouds as a tailwind.

July 9, 2026

1 min read

Source: Insider Monkey

Jim Cramer, host of CNBC's Mad Money, made a bullish call on Johnson & Johnson (NYSE:JNJ) during a recent episode, predicting positive developments for the company's blockbuster drugs. "You're going to see some massive moves in real time for no reason whatsoever," Cramer said, hinting at potential upside surprises.

Key Highlights

Cramer emphasized AI opportunities in neoclouds as a supportive factor for healthcare stocks, particularly JNJ. He believes the company's strong portfolio of blockbuster drugs will generate a wave of positive news.

Context

The comments come as J&J continues to advance its pipeline in oncology, immunology, and neuroscience. The stock is trading near all-time highs, with a generally positive analyst consensus.

What It Means for Investors

Cramer's optimism reflects confidence in J&J's innovation-driven growth, but investors should weigh fundamentals before making decisions.

Frequently Asked Questions

Jim Cramer said he expects positive news about the company's blockbuster drugs and highlighted AI opportunities in neoclouds as a tailwind.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.